Company news

Recursion Pharmaceuticals, Inc. news in 2022

Recursion Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results

November 7, 2022

Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB

October 24, 2022

Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022

September 12, 2022

Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum

August 17, 2022

Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results

August 8, 2022

Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

July 20, 2022

Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference

June 19, 2022

Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results

May 9, 2022

Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

April 10, 2022

Recursion Publishes First Environmental, Social and Governance (ESG) Report

March 23, 2022

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

March 22, 2022

Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation

March 17, 2022

Recursion Provides Updated Guidance on Clinical Trial Starts

March 2, 2022

Decks in 2022